Non-Invasive Preimplantation Genetic Screening for Aneuploidies and Clinical Outcomes in Egg Donation Patients
ConditionIVF
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-50
SponsorInstituto Bernabeu
About this trial
Preimplantation genetic testing for aneuploidies (PGT-A) is commonly used in IVF but requires embryo biopsy and shows limited benefit in egg donation cycles. Non-invasive PGT-A (niPGTA), based on the analysis of cell-free embryonic DNA in spent culture media, offers a promising biopsy-free alternative. This prospective, blinded study in egg donation cycles will evaluate whether niPGTA-detected aneuploidy is associated with implantation failure and pregnancy loss, assessing its potential clinical value as a non-invasive embryo selection tool.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Women between 18 and 50 years old who are oocyte recipients.
Signed consent form
Transfer of a single blastocyst-stage embryo
Male with normal sperm FISH
Disqualifiers
Uterine malformations
Abnormal karyotypes in either partner
Failure to sign informed consent
Trial population
Patients who are going to undergo an oocyte donation cycle, who meet the inclusion/exclusion criteria and who sign the informed consent form
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Live birth rate
Time frame
9 months from enrolmentSecondary outcomes
1
Pregnancy rate
Time frame
2 weeks from enrolment2
Miscarriage rate
Time frame
12 weeks from enrollmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov